Karydo TherapeutiX

What Karydo TherapeutiX does

Karydo TherapeutiX, Inc. (株式会社Karydo TherapeutiX, traded as KarydoTX) is a Tokyo-based biotechnology company founded in October 2015 by Scientific Founder and Chair Dr. Thomas N. Sato to commercialize intellectual property developed under the JST ERATO Sato Live Bio-Forecasting Project. The company's central product is the Precision Human Digital-Twins System (Precision hDTS), a platform conceived to measure molecular, cellular, organ, and inter-organ information inside the body in real time, model the individual in a digital twin, and deliver targeted prevention and treatment at the earliest stage of dysfunction. The company sells into pharmaceutical companies (drug discovery support, biomarker discovery, target identification), food and beverage companies (functional-food safety and efficacy), academic medical institutions (clinical research and biomarker validation), and government research programs; current activity centers on services and collaborative research rather than commercial product sales.

The technical stack integrates four co-developed modules—sensor nano-machines, therapeutic nano-machines, an individual digital-twin model, and a milli-scale implantable relay device—underpinned by four proprietary AI platforms: hMDB (humanized Mouse DataBase), which predicts human drug safety, side effects, and efficacy from mouse multi-organ transcriptome data without prior knowledge of structure or mechanism; D-iOrgans Atlas, a body-wide transcriptome atlas for mapping inter-organ disease mechanisms; a proprietary bio-generative AI platform applied to idiopathic pulmonary fibrosis; and Virtual Human InformatiX (vHX), used for virtual drug discovery and clinical-trial simulation, including identification of 88 COVID-19 candidate therapeutics. Capability is published in iScience (2018, 2020), Scientific Reports (2023), and PLOS Genetics (2024).

The business model combines collaborative research fees, technology licensing (e.g., the UTSD:0672 Tie2-GFP transgenic mouse previously licensed to Genentech, Novartis, Sanofi, Bayer, Merck, Jackson Laboratory, and Monsanto), fee-for-service biomarker discovery, and virtual drug discovery projects. Distribution is sales-led and partnership-driven: Nagara Sangyo (長瀬産業) acts as the primary distribution agent for KTX technology inquiries and joint research; direct collaborations are maintained with universities (Nara Medical University, Kyoto University) and clinical research sites (National Hospital Organization centers and Shinshu University). Pricing is not publicly disclosed. A material share of operating activity is supported by Japanese non-dilutive government programs including JST ERATO, PRISM, KAKENHI, the Security Technology Research Promotion System, Nakatani Foundation grants, and Tokyo Metropolitan and Kyoto Chamber of Commerce & Industry SME grants.

Name

Karydo TherapeutiX

Legal name

Karydo TherapeutiX株式会社 (Karydo TherapeutiX, Inc.)

Website

https://karydo-tx.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

Karydo TherapeutiX is a Tokyo-based biotech developing the Precision Human Digital-Twins System and proprietary bio-generative AI platforms that enable real-time disease detection, biomarker discovery, and virtual drug discovery for pharmaceutical, food and beverage, academic, and government research clients.

Ownership category

akta.pro rank

Product category

AI-Driven Drug Discovery

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345), Custom Computer Programming Services (541511)

SIC

Laboratory Analytical Instruments (3826), In Vitro & In Vivo Diagnostic Substances (2835), Surgical & Medical Instruments & Apparatus (3841)

akta.pro industry

PRIMARYHLAGAJAO

AI/ML Platforms for Drug Discovery & Experiment Optimization

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

SECONDARYHLAAAIAE

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)

Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

SECONDARYHLAAALAL

Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)

Healthcare & Life Sciences/Biotechnology & Biologics/Diagnostics (Biotech-related)

Keywords

• AI drug discovery
• Precision medicine
• Human digital twins
• Biomarker discovery
• Therapeutic nanomedicine

Headquarters

HQ city

Tokyo

HQ country

Japan

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations

Revenue model

1. Collaborative Research: The company conducts collaborative research with pharmaceutical companies, food/beverage companies, and business/trading companies. Prior to 2009, collaborations included Regeneron Pharmaceuticals, ImClone Systems, Monsanto, Surface Logix, Daiichi Sankyo, and Asubio Pharma. Post-2009 collaborations with major international companies remain undisclosed under confidential agreements.
2. Technology Licensing: Licensing of proprietary technologies including the Tie2-GFP transgenic mouse (UTSD:0672) to biotechnology and pharmaceutical companies such as Genentech, Novartis, Sanofi, Bayer, Jackson Laboratory, Monsanto, and Merck.
3. Biomarker Discovery Services: Joint research services for biomarker discovery using proprietary AI platforms to identify early markers for diseases such as atherosclerosis and myocardial infarction from personal biological information and lifestyle records.
4. Drug Discovery Support: Virtual drug discovery and clinical trial services using AI platforms. Provided COVID-19 therapeutic candidate analysis to pharmaceutical companies under confidentiality agreements.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Karydo TherapeutiX develops the Precision Human Digital-Twins System (Precision hDTS), an AI-driven platform that integrates sensor and therapeutic nano-machines, a digital twin of the patient, and a milli-scale implantable device to enable precision drug discovery and personalized therapeutic intervention. The company also offers supporting AI platforms—hMDB, vHX, D-iOrgans Atlas, and a Bio-Generative AI Platform—used for humanized mouse data analysis, virtual human organ simulation, and disease-state modeling. Its offerings serve pharmaceutical, food/beverage, and academic research clients across drug discovery, biomarker identification, and toxicity evaluation workflows.

Product overview

Karydo TherapeutiX develops the Precision Human Digital-Twins System (Precision hDTS), a unified platform composed of four integrated modules: Sensor Nano-Machines, Therapeutic Nano-Machines, Digital-Twin of Oneself, and Milli-Scale Implantable Device. The company also offers multiple AI platforms — hMDB (humanized Mouse DataBase) for predicting drug side effects and efficacy, D-iOrgans Atlas for body-wide transcriptome analysis, a proprietary Bio-Generative AI Platform for disease mechanism discovery, and Virtual Human InformatiX (vHX) for virtual drug discovery and clinical trial simulation. These platforms collectively enable early disease detection, biomarker and therapeutic target discovery, and personalized prevention and treatment.

Differentiator

Problem solved

Functional benefit

Products and services

• Precision Human Digital-Twins System (Precision hDTS)

Quantifiable outcome

• 88 candidate pharmaceuticals identified for COVID-19 treatment using Virtual Human InformatiX (vHX) platform
• +2 more outcomes

Named customers8 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature8 records

Partnerships

Nine partnerships are on record, tiered core, secondary and minor.

• Nagara Sangyo Co., Ltd. (長瀬産業株式会社)coreChannel Partner/ Reseller/ Distributor · 10 May 2021Distribution partnership established in 2020 for sales of KTX technologies including vHX platform. Nagase Sangyo serves as primary contact for inquiries about KTX technologies and joint research. Also conducting joint biomarker discovery research targeting 27 diseases including arteriosclerosis and myocardial infarction using personal biological information and lifestyle data.
• Nara Medical UniversitycoreStrategic or Co-development PartnerAcademic collaboration establishing V-iCliniX (Virtual Human InformatiX Clinic) endowed department at Nara Medical University. Dr. Sato serves as Professor. Purpose: development of technology to predict disease onset and systemic drug effects in real-time without invasive procedures, and cultivating talent for regional society.
• International Telecommunications Basic Technology Research Institute (ATR)coreStrategic or Co-development PartnerHost institution for Thomas N. Sato BioMEC-X Laboratories. Dr. Sato serves as Director of Sato Special Research Institute at ATR. Long-standing research partnership.
• Kyoto UniversitysecondaryStrategic or Co-development PartnerCollaborative research with Dr. Tatsuya Akutsu (Professor, Institute for Chemical Research) on tree edit distance with variables for measuring similarity between mathematical formulas. Paper published on arXiv.
• National Hospital Organizations (国立病院機構)secondaryStrategic or Co-development PartnerClinical research collaborations with NHO Kure Medical Center, Hiroshima-Nishi Medical Center, and Shikoku Medical Center for Children and Adults.
• Shinshu University School of MedicinesecondaryStrategic or Co-development PartnerClinical research collaboration with Department of Cardiovascular Medicine.
• Regeneron Pharmaceuticals, Inc.secondaryStrategic or Co-development PartnerIndustrial collaboration (until 2009) in molecular biology research.
• ImClone Systems IncorporatedsecondaryStrategic or Co-development PartnerIndustrial collaboration (until 2009) in biotechnology research.
• Surface Logix, Inc.minorStrategic or Co-development PartnerIndustrial collaboration (until 2009) in biotechnology. Dr. Sato served on Scientific Advisory Board (2006-2008).

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Regional players

• Preferred Networks: Preferred Networks is a Japanese AI company applying deep learning to drug discovery, materials science, and robotics. Like Karydo, it is a Japan-based AI-for-science player targeting pharma/biotech applications and represents the most direct domestic comparable in the Japanese ecosystem.

Emerging players

• Personalis: Personalis is a cancer genomics company offering multi-omics and immuno-genomics assays for pharma and clinical use. Comparable to Karydo's D-iOrgans Atlas in its emphasis on comprehensive multi-organ/whole-transcriptome data generation for pharma R&D.
• CytoReason: CytoReason builds AI models of the human immune system and disease biology to support pharma R&D and clinical trials. Its cell-level disease modeling is comparable to Karydo's D-iOrgans Atlas and Bio-Generative AI approach to inter-organ mechanism discovery.
• GNS Healthcare: GNS Healthcare applies causal AI to multi-omics and clinical data to model disease and predict drug response. Comparable to Karydo's AI-driven approach to biomarker discovery and prediction of drug side effects using proprietary biological data assets.

Direct peers

• XtalPi: XtalPi combines AI, quantum physics, and cloud computing for drug discovery and prediction of small-molecule properties. Like Karydo's hMDB and vHX, XtalPi offers AI-based prediction of drug efficacy and safety, serving global pharma clients.
• Insitro: Insitro uses machine learning and high-throughput biology to build predictive disease models and accelerate drug discovery. Both companies combine AI with biological data to predict drug outcomes and identify novel therapeutic targets, and both target pharma partnerships.
• Recursion Pharmaceuticals: Recursion is a leading AI-driven drug discovery company combining high-throughput biology with machine learning to identify novel therapeutics. Like Karydo, Recursion leverages proprietary biological data and AI to predict drug efficacy and side effects, and pursues pharma partnerships for pipeline development.
• BenevolentAI: BenevolentAI applies AI to biomedical knowledge graphs to identify novel drug targets and indications. Both companies leverage proprietary AI to discover novel therapeutic mechanisms and biomarker-target relationships for pharma collaborators.
• Schrödinger: Schrödinger provides computational chemistry and physics-based simulation software for drug discovery and materials science. Both companies offer AI/in silico platforms used by pharma companies to predict drug efficacy and side effects, though Schrödinger is more focused on molecular simulation.

Broad incumbents

• Tempus AI: Tempus is a precision medicine company that combines multi-omics data, AI, and clinical records to support diagnostics and drug discovery. While much larger and more diagnostics-focused, Tempus shares the AI + multi-omics + biomarker discovery positioning with Karydo's platforms.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInjp.linkedin.com/in/thomas-n-sato-9b242134
• Xx.com/karydotx
• Facebookfacebook.com/profile.php

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Karydo TherapeutiX